New Delhi, October 03, 2026: Mankind Pharma has extended ₹1 crore in financial support to Captain Smit Macchhar and his family, in recognition of his extraordinary courage, composure and sense of responsibility demonstrated during a moment of unprecedented crisis.
The gesture reflects Mankind Pharma’s belief that acts of exceptional courage deserve more than words of appreciation. The company has chosen to translate its gratitude into meaningful action, recognizing Captain Smit’s commitment to the safety and well-being of those entrusted to his care.
Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said: “There are moments when words of appreciation simply do not feel enough. Captain Smit Macchhar’s courage, composure and unwavering sense of responsibility have deeply moved us at Mankind Pharma. In a moment of extraordinary crisis, he put the safety and well-being of others before himself, demonstrating the very best of leadership and service. At Mankind, we believe that actions speak louder than words, and that meaningful recognition is best expressed when appreciation is accompanied by action. We wanted our gratitude to go beyond words and take the form of meaningful support for him and his family. We salute his courage, his humanity and his unwavering commitment to those entrusted to his care.”
The support to Captain Smit and his family is being extended as a gesture of gratitude for his courage and leadership, and in recognition of the responsibility he demonstrated towards the lives entrusted to him.
Earlier this year, on the first anniversary of Operation Sindoor, Rajeev Juneja contributed ₹9.17 crore reaffirming his continued personal commitment to supporting those who serve the nation.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. Mankind’s distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740+ scientists
